158 related articles for article (PubMed ID: 34158265)
41. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
42. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.
Miller KC; Gertz MA; Buadi FK; Hayman SR; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Muchtar E; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2019 Dec; 54(12):2039-2050. PubMed ID: 31190005
[TBL] [Abstract][Full Text] [Related]
43. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
44. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
45. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.
Vogl DT; Wang T; Pérez WS; Stadtmauer EA; Heitjan DF; Lazarus HM; Kyle RA; Kamble R; Weisdorf D; Roy V; Gibson J; Ballen K; Holmberg L; Bashey A; McCarthy PL; Freytes C; Maharaj D; Maiolino A; Vesole D; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1765-74. PubMed ID: 21624486
[TBL] [Abstract][Full Text] [Related]
46. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
47. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
48. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.
Chan H; Phillips M; Maganti M; Farooki S; Piza Rodriguez G; Masih-Khan E; Chen C; Prica A; Reece D; Tiedemann R; Trudel S; Kukreti V
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):225-234. PubMed ID: 29397346
[TBL] [Abstract][Full Text] [Related]
49. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
50. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
51. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
J Hematol Oncol; 2015 Jul; 8():80. PubMed ID: 26138828
[TBL] [Abstract][Full Text] [Related]
52. The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients.
Sarıcı A; Erkurt MA; Kuku İ; Bahçecioğlu ÖF; Biçim S; Kaya E; Berber İ; Keser MF; Gök S; Özgül M
Transfus Apher Sci; 2022 Feb; 61(1):103296. PubMed ID: 34696982
[TBL] [Abstract][Full Text] [Related]
53. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
54. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
55. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
[TBL] [Abstract][Full Text] [Related]
56. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
[TBL] [Abstract][Full Text] [Related]
58. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI; McMillan A; Negrin RS; Horning SJ; Laport GG
Biol Blood Marrow Transplant; 2008 Jul; 14(7):741-7. PubMed ID: 18541192
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
[TBL] [Abstract][Full Text] [Related]
60. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Badar T; Hari P; Dávila O; Fraser R; Wirk B; Dhakal B; Freytes CO; Rodriguez Valdes C; Lee C; Vesole DH; Malek E; Hildebrandt GC; Landau H; Murthy HS; Lazarus HM; Berdeja JG; Meehan KR; Solh M; Diaz MA; Kharfan-Dabaja MA; Callander NS; Farhadfar N; Bashir Q; Kamble RT; Vij R; Munker R; Kyle RA; Chhabra S; Hashmi S; Ganguly S; Jagannath S; Nishihori T; Nieto Y; Kumar S; Shah N; D'Souza A
Cancer; 2021 Jan; 127(1):82-92. PubMed ID: 32966625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]